StockData
Greenwich LifeSciences, Inc. logo

Greenwich LifeSciences, Inc. (GLSI) stock

GLSINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026Score 6/30
$18.70+4.94 (+35.90%)

Close on Nov 17, 2026Market cap $274.48MP/E –Yield –

Greenwich LifeSciences operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Greenwich LifeSciences's operating cash flow for the twelve months ending Jun 30, 2026 was -$12.49M. For fiscal 2025 it was -$9.91M. The highest annual figure on record is -$293.27K in fiscal 2019.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$9.91M–
FY2024Dec 31, 2024-$7.27M–
FY2023Dec 31, 2023-$6.48M–
FY2022Dec 31, 2022-$6.20M–
FY2021Dec 31, 2021-$4.29M–
FY2020Dec 31, 2020-$1.15M–
FY2019Dec 31, 2019-$293.27K–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$1.94M–
Q1 FY2026Mar 31, 2026-$4.70M–
Q4 FY2025Dec 31, 2025-$3.17M–
Q3 FY2025Sep 30, 2025-$2.67M–
Q2 FY2025Jun 30, 2025-$2.23M–
Q1 FY2025Mar 31, 2025-$1.83M–
Q4 FY2024Dec 31, 2024-$1.85M–
Q3 FY2024Sep 30, 2024-$2.58M–
Q2 FY2024Jun 30, 2024-$1.05M–
Q1 FY2024Mar 31, 2024-$1.78M–
Q4 FY2023Dec 31, 2023-$2.15M–
Q3 FY2023Sep 30, 2023-$1.80M–
Q2 FY2023Jun 30, 2023-$966.98K–
Q1 FY2023Mar 31, 2023-$1.56M–
Q4 FY2022Dec 31, 2022-$2.17M–
Q3 FY2022Sep 30, 2022-$1.55M–
Q2 FY2022Jun 30, 2022-$532.70K–
Q1 FY2022Mar 31, 2022-$1.95M–
Q4 FY2021Dec 31, 2021-$2.26M–
Q3 FY2021Sep 30, 2021-$894.64K–
Q2 FY2021Jun 30, 2021-$604.32K–
Q1 FY2021Mar 31, 2021-$528.27K–
Q4 FY2019Dec 31, 2019-$214.17K–

More Greenwich LifeSciences figures

See a number that looks wrong?